Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS) | Zendy

Yukito Shinohara | Zendy; K Nishimaru | Zendy; Tohru Sawada | Zendy; Akiro Terashi | Zendy; Shunnosuke Handa | Zendy; Shunsaku Hirai | Zendy; Kunihiko Hayashi | Zendy; Hideo Tohgi | Zendy; Yasuo Fukuuchi | Zendy; Shinichiro Uchiyama | Zendy; Takenori Yamaguchi | Zendy; Shotai Kobayashi | Zendy; Kazuoki Kondo | Zendy; E Otomo | Zendy; Fumio Gotoh | Zendy

Open Access

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

Author(s) -

Yukito Shinohara,

K Nishimaru,

Tohru Sawada,

Akiro Terashi,

Shunnosuke Handa,

Shunsaku Hirai,

Kunihiko Hayashi,

Hideo Tohgi,

Yasuo Fukuuchi,

Shinichiro Uchiyama,

Takenori Yamaguchi,

Shotai Kobayashi,

Kazuoki Kondo,

E Otomo,

Fumio Gotoh

Publication year - 2008

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.107.505131

Subject(s) - medicine , aspirin , hazard ratio , stroke (engine) , cerebral infarction , clinical endpoint , myocardial infarction , infarction , cardiology , anesthesia , surgery , randomized controlled trial , confidence interval , ischemia , mechanical engineering , engineering

The antiplatelet agent sarpogrelate is a selective inhibitor of 5-hydroxytryptamine receptors. The purpose of this study was to compare the efficacy and safety of sarpogrelate with those of aspirin in Japanese ischemic stroke patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research